Novo Nordisk: 2024 Earnings Review
Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.
Novo Nordisk price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan
JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
DelveInsight Business Research, LLP: Global Biologics Drug Substance Manufacturing Market to Exhibit Growth at a CAGR of ~11% by 2032 | DelveInsight
The biologics drug substance manufacturing market is witnessing substantial expansion, largely due to the growing prevalence of chronic diseases, which is driving the need for biologics development ...
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...
Novo Resources Corp. Business Review
VANCOUVER, British Columbia and PERTH, Australia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- HIGHLIGHTS – FOURTH QUARTERThree new high ...
Jim Cramer Says Eli Lilly and Company (LLY)’s ‘Doing Quite Well’
He also sardonically targeted co-host David Faber and said “Look I’m sure that when they discovered the cotton gin, and ...
Jim Cramer on Eli Lilly and Company (LLY): ‘I Remain Steadfast’
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...